Resource impact information

Following the publication of NICE technology appraisal guidance on risankizumab (TA596) for treating moderate to severe plaque psoriasis, a NEW local resource impact template has been published to include all current NICE recommended treatments for this patient group


This page was last updated: 20 January 2020